NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.5 CHF | +1.91% |
|
+4.41% | +11.35% |
| 06-05 | Cytokinetics CEO Says Board Would Have Backed Actionable Buyout | DJ |
| 06-05 | The odds of rates getting cut in 2024 may be better than you think |  |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
18/06/2024
- Citi European Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
105.7
USD
Average target price
110.1
USD
Spread / Average Target
+4.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.35% | 213B | |
| +42.69% | 750B | |
| +34.11% | 606B | |
| -6.87% | 356B | |
| +18.74% | 326B | |
| +6.76% | 286B | |
| +18.08% | 246B | |
| -3.44% | 213B | |
| +2.64% | 167B | |
| +6.72% | 165B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : Incyte 'Disappointed' After Planned COVID-19 Therapy Fails to Meet Target in Late-Stage Study
